Veterans Experience Adverse Kidney & Cardiovascular Outcomes Across Three GLP1s Prescribed For Type 2 Diabetes

Negative kidney and cardiovascular disease outcomes were similar among veterans with type 2 diabetes who were taking three types of glucagon-like peptide-1 receptor agonists (GLP-1s), according to a recent comparative effectiveness study. The comparison included liraglutide (brand names Saxenda and Victoza), semaglutide (brand names Ozempic, Wegovy, and Rybelsus), and dulaglutide (brand name Trulicity).

The comparison of the three GLP-1 medications included 21,790 veterans with type 2 diabetes, with varying levels of kidney function, but not end-stage kidney disease, who were treated with metformin. They started liraglutide, semaglutide, or dulaglutide between January 1, 2018, and . . .